Global InformationBionovo information
 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Headquarters | Emeryville, CA , United States |
Key people | Isaac Cohen, Founder and CEO, Mary Tagliaferri, Founder, President and CMO |
Number of employees | 8[1] |
| Website | www |
Bionovo (NASDAQ: BNVI.OB) was an American biotechnology company focused on the discovery and development of botanically derived treatments for women's health and cancer based in Emeryville, California. The company had multiple drug candidates in U.S. Food and Drug Administration (FDA) clinical trials- Menerba (formerly known as MF101) a selective estrogen receptor beta agonist for hot flashes associated with menopause Seala (formerly VG101) a selective estrogen receptor beta agonist for menopausal vaginal dryness and Bezielle (formerly BZL101) for advanced breast cancer. The company has ceased activity after filing for Chapter 7 bankruptcy protection in California. Bionovo's stock is no longer listed.
- ^ "source". Biz Journals. Retrieved 24 July 2012.